Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy

Despite recent advances, the efficacy of androgen/androgen receptor (AR)-targeted therapy remains  limited for many patients with metastatic prostate cancer. This is in part because prostate cancers adaptively switch to the androgen/AR-independent pathway for survival and growth, thereby conferring...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Nat Commun
Glavni autori: Geng, Hao, Xue, Changhui, Mendonca, Janet, Sun, Xiao-Xin, Liu, Qiong, Reardon, Patrick N., Chen, Yingxiao, Qian, Kendrick, Hua, Vivian, Chen, Alice, Pan, Freddy, Yuan, Julia, Dang, Sang, Beer, Tomasz M., Dai, Mu-Shui, Kachhap, Sushant K., Qian, David Z.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2018
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6255907/
https://ncbi.nlm.nih.gov/pubmed/30478344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-018-07411-7
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items